FindDrugs.org

Ro Herpes / HSV Review

Herpes / HSV · Reviewed Sep 14, 2026

6.78/10
Ro operator trust7.34/10See the full Ro brand review
Insurance-friendlyNo commitmentCash-pay

Our verdict

Ro treats HSV with generic valacyclovir for both genital herpes and cold sores, on daily-suppressive or episodic plans. It stands out for requiring an in-person diagnosis of a first outbreak before remote treatment — a responsible clinical gate. Pricing is partly shown (cold sores from $29/mo) and partly gated.

Price

from $29/mo · 2 plans

Check price

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

Key takeaways

  • Generic valacyclovir, daily or episodic
  • Requires in-person diagnosis of a first outbreak
  • Cold-sore plans from $29/mo; genital-herpes pricing gated

What is Ro Herpes / HSV?

Ro's herpes program prescribes generic valacyclovir for genital herpes (HSV-2) and cold sores (HSV-1), on daily-suppressive or as-needed episodic plans, after an online visit — with a first outbreak requiring in-person diagnosis before Ro will treat remotely.

Treatment options

Prices as of Sep 14, 2026 — verify current on the brand's site.

Methodology scorecard

Scored on Sep 14, 2026 under methodology v6

6.78/10

Coverage: Checked against 6 recorded withdrawals. Marking matches the wording each withdrawal was recorded in, so the same claim stated differently is not marked.

One factor could not be established: Legitimacy & Accreditation

We could not establish this from a third-party record. What we searched: accreditation and licensing bodies — LegitScript, NABP including its .pharmacy verification, and URAC — state licensing registries, and the provider’s own corporate disclosures. On LegitScript we read the provider’s own website and never LegitScript’s register: their terms do not permit automated queries to it, so a LegitScript-issued seal found on a provider’s pages establishes that the seal was displayed there on that date, and not that a certification is current. No register, federal or otherwise, answers whether an operation is licensed in every state it ships to; of the six government hosts we read on 2026-08-25, three do not permit us. This is a statement about what we were able to verify, never a finding that the provider lacks accreditation. Where a provider states its own licensure or displays its own seal, that is recorded as the provider’s own claim and lifts no subscore by itself.

  • Clinical Oversight & Safety
    Critical

    Evidence (as scored Sep 14, 2026): US-licensed providers review an online questionnaire and prescribe when appropriate. — Ro (ro.co), Aug 13, 2026

  • Sourcing Transparency & Legal Context
    High

    Evidence (as scored Sep 14, 2026): Your first outbreak should be diagnosed by an in-person medical provider before Ro can provide remote treatment. — Ro — Genital Herpes, Jul 30, 2026

  • Data Privacy & Security
    Medium

    Evidence (as scored Sep 14, 2026): Operates as a HIPAA-covered US telehealth provider with a published privacy policy; no major breach identified in retrieval. — Ro (ro.co), Jul 24, 2026

  • Pricing Transparency & Value
    Critical

    Evidence (as scored Sep 14, 2026): Starting at $29/month on a recurring plan* ... Dosing minimums apply — Ro — Cold Sores, Jul 30, 2026

  • Policy Clarity & Fairness
    High

    Evidence (as scored Sep 14, 2026): Cancellation stops future renewals and refunds are issued if medication is never prescribed, but membership is non-refundable once billed and prescription medication sales are final; billing complaints recur. — Better Business Bureau — customer reviews, Jul 24, 2026

  • Quality-under-Growth
    Medium

    Evidence (as scored Sep 14, 2026): Rapid scaling with millions of patients, but recurring customer-service, billing, and shipping complaints suggest support strain under growth. — Better Business Bureau — customer reviews, Jul 24, 2026

  • Access & Speed
    Medium

    Evidence (as scored Sep 14, 2026): Cash-pay medication can ship in under a week; insurance-routed prescriptions take about 2-3 weeks with concierge support. — Ro (ro.co), Jul 24, 2026

  • Transparency & Disclosure
    Critical

    Evidence (as scored Sep 14, 2026): Does not name the fulfilling pharmacy or the individual prescribing clinicians. — Ro (ro.co), Aug 13, 2026

  • Support & Care Model
    Supporting

    Evidence (as scored Sep 14, 2026): Offers ongoing provider check-ins and a dedicated insurance concierge, but customer-service responsiveness is a common complaint. — Ro (ro.co), Jul 24, 2026

Pricing & cancellation

Check price

All-in price

from $29/mo · 2 options

Cost structure
Month-to-month membership with optional prepaid annual plan.
Insurance vs. cash
Cash-pay
Deal structure
Cancellation
Cancel anytime to stop future renewals; membership fee non-refundable once billed for the current cycle.
Forced subscription
Not required

Pros & cons

Pros

  • Genuine clinician review with real prescriber oversight
  • Large, well-funded, high-momentum operator
  • Broad treatment catalog under one account
  • Discreet, free shipping

Cons

  • Membership billed separately from medication cost
  • Pricing frequently gated behind the intake quiz
  • Compounding pharmacies not named in any category
  • Heavy promotion of non-FDA-approved compounded formulations

Safety

Talk to a licensed clinician

Valacyclovir is generally well tolerated; headache and nausea are the most common effects. Ro requires an in-person first-outbreak diagnosis before prescribing remotely.

The bottom line

A sensible, no-frills HSV option from a legitimate operator, with a responsible diagnosis gate. Newly reviewed — proposed pending approval.

Check price

We may earn a commission if you sign up through this link. It never affects rankings or scores. Not medical advice.

See how Ro ranks among Herpes providers

What changed & why

This brand's own history — every re-review and methodology recompute, logged. Rankings change when the evidence or the rules change, never for payment. See the site-wide methodology ledger for version history.

  1. Sep 14, 2026Methodologymethodology v66.766.78

    We changed how this score is calculated, and Herpes / HSV score moved from 6.76 to 6.78. 1 of the factors behind it moved. How we score.

    1 factor withdrawn — assessed coverage fell 10 → 9. Part of any score movement here reflects evidence we retracted, not a change in the brand.

  2. Aug 23, 2026Methodologymethodology v37.126.76

    We changed how this score is calculated, and Herpes / HSV score moved from 7.12 to 6.76. 2 of the factors behind it moved. How we score.

    2 factors withdrawn — assessed coverage fell 12 → 10. Part of any score movement here reflects evidence we retracted, not a change in the brand.

Work at Ro?

If something here is wrong or out of date, send us a correction request. We read every one and decide what changes — it does not edit the review or move a score.

Sources & how we researched this

Scored on 9 of 11 factors · 5 sources cited

Brand site

Reviews

What we couldn't verify

  • Fulfilling pharmacy and 503A/503B compounding pharmacy are not identified in any record we could retrieve.
  • Privacy/security posture rests on standard HIPAA-covered-telehealth assumptions; no independent audit trail was retrievable.
  • Individual prescribing clinician identities were not found in any record we could retrieve.
  • Withdrawn — Ro is LegitScript-certified. WITHDRAWN. legitscript.com/websites/ro.co/ returns HTTP 200 but serves a reCAPTCHA form shell with no certification status and no mention of ro.co (retrieved 2026-08-13); api.legitscript.com returns 403, seal-ID routes 404, the sitemap is empty, and ro.co's own badge is an unlinked image. The prior citation was the legitscript.com HOMEPAGE, which states nothing about Ro. Retrieval-failed, not disproved — the same test fridays failed with a 403.
  • Withdrawn — Ro funding/revenue figures (raised, valuation, revenue, projections). WITHDRAWN. Sourced only to sacra.com, a market-data aggregator that neither originates nor audits the figures. Ro is private; no filing or audited record is retrievable.
  • Withdrawn — Ro is a "preferred distribution partner" of Novo Nordisk and Eli Lilly. WITHDRAWN. Cited to press/affiliate only. Not re-pointable: novocare.com (200) names Ro on no fetchable page and lillydirect.lilly.com returns HTTP 403 (retrieval-failed). Ro's own claim to source through those channels is retained as company-attested.
  • Withdrawn — Ro surfaces contraindication warnings during intake. WITHDRAWN. A safety-behaviour claim resting on the company's own page; no label or registry record can establish what a telehealth intake surfaces.
  • Withdrawn — Ro operates provider-managed dose titration with starter-dose offerings and ongoing check-ins. WITHDRAWN and the factor EXCLUDED. A dosing claim requires a label or registry record; none describes a telehealth provider's titration practice.
  • Withdrawn — Ro "discloses membership terms, contraindications, and expected outcomes with cited studies". WITHDRAWN. A favourable disclosure-quality claim resting solely on Ro's own page; a label records what the contraindications are, not that Ro surfaces them, so it is not re-pointable (punch list § G9).
Last reviewed Sep 14, 2026 · methodology v6View the ledger

Top pick

Ro 6.78/10